Petrelli F et al. – The meta–analysis suggests that in recurrent/metastatic head and neck cancer the addition of anti–epidermal growth factor receptor (EGFR) monoclonal antibodies to standard therapy confers a statistically significant improvement in overall survival (OS), progression–free survival (PFS), and overall response rate. [more...]
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close